Northwest Biotherapeutics (NWBO) Capital Expenditures Growth (1y) (2011 - 2026)
Northwest Biotherapeutics (NWBO) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 143.40% |
| 10 | Northwest Biotherapeutics | 277.19 Mn | 275.40 Mn | - | 38.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.71% |
| Dec 31, 2025 | 1,060.26% |
| Sep 30, 2025 | 14.77% |
| Jun 30, 2025 | -41.65% |
| Mar 31, 2025 | -61.09% |
| Dec 31, 2024 | -81.34% |
| Sep 30, 2024 | -59.73% |
| Jun 30, 2024 | -58.29% |
| Mar 31, 2024 | -82.07% |
| Dec 31, 2023 | -80.65% |
| Sep 30, 2023 | 58.33% |
| Jun 30, 2023 | 206.13% |
| Mar 31, 2023 | 2,198.28% |
| Dec 31, 2022 | 39.09% |
| Sep 30, 2022 | -89.74% |
| Jun 30, 2022 | -72.93% |
| Mar 31, 2022 | -78.03% |
| Dec 31, 2021 | -49.28% |
| Sep 30, 2021 | 20.03% |
| Jun 30, 2021 | 21.14% |